skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

How Pharma Copes with the Pain of Developing Abuse-Deterrent Opioids

With the wide availability of generic opioid analgesics, such as oxycodone and hydromorphone, the abuse of prescription opioids has become a major public health problem in the US. Consequently, in January 2013, the FDA released draft guidance for drug makers that mandates inclusion of abuse-deterrent technology for new opioid products. Data from Pharmaprojects and Trialtrove were analyzed to explore the current development for opioid analgesics with abuse-deterrent technology in order to gain insight into the front runners of this competitive area, their characteristics, and the top sponsors on the verge of becoming market leaders.

One of the most common approaches in abuse-deterrent technology is the development of new formulations of extended-release opioids, or tamper resistant properties that render the drugs difficult to crush, grind, and dissolve for injection or nasal insufflation by potential abusers.

Find out more. Download whitepaper below.


Abuse-deterrent

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。